Geron Corporation published a document analyzing the correlation between treatment-emergent cytopenias and clinical response with imetelstat in patients with lower-risk myelodysplastic syndromes. The document includes data from the IMerge trial and examines clinical consequences such as bleeding, infection, and febrile neutropenia. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.